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1. Introduction
Subclinical hypothyroidism, defined as a mild degree of thyroid dysfunction biochemically,
is a common clinical disease. It is marked by elevated serum concentrations of thyroid stim‐
ulating hormone (TSH) and normal serum concentrations of free thyroxine (fT4) and triiodo‐
thyronine (T3). Subclinical hypothyroidism can be divided into two categories, depending
on the magnitude of the increase in serum TSH, with concentrations of 4.5-10 mU/L consid‐
ered mild disease and TSH >10 mU/L considered severe disease. However, the definition
and clinical significance of subclinical hypothyroidism are confounded by controversies
over the exact upper limit of the reference range for se um TSH.
Subclinical hypothyroidism occurs in 4-20% of the adult population, a wide range that re‐
sults from differences in age, gender, body-mass index, race, dietary iodine intake, and the
cut-off concentrations of serum TSH used to define this condition. For example, most epide‐
miological surveys have reported that the prevalence of mild thyroid dysfunction was high‐
er in older than in younger populations. In addition, overt or subclinical hypothyroidism
occurs more frequently in areas of abundant iodine intake than in iodine-deficient areas,
suggesting that iodine supplementation may increase the incidence of this disease. Subclini‐
cal hypothyroidism may be persistent or transient. In some of these patients, the transient
expression of TSH-receptor blocking antibodies may indicate the recovery of thyroid func‐
tion. Thus, it may be reasonable to reassess antibodies to thyroid hormones, including TSH-
receptor blocking antibodies, in patients previously diagnosed with hypothyroidism to
determine whether the latter is transient or permanent.
On average, 2-28% of patients with subclinical hypothyroidism progress to overt hypothyr‐
oidism, depending on age, gender, and the presence of anti-thyroid antibodies. However,
baseline TSH concentration has been shown to be the most significant factor associated with
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progression to overt hypothyroidism. For example, a recent prospective study reported that
the rate of overt hypothyroidism was about 10% in the entire study population, but was 2%,
20%, and 73% in patients with initial TSH concentrations of 5.0-9.9 mU/L, 10.0-14.9 mU/L,
and 15.0-19.9 mU/L, respectively.
Subclinical hypothyroidism may be associated with depressed systolic function at rest and
left ventricular diastolic dysfunction at rest and during exercise. Persistent subclinical hypo‐
thyroidism may also affect the vascular smooth muscle cells, increasing systemic vascular
resistance and arterial stiffness. Studies on the risks of cardiovascular disease and mortality
due to coronary heart disease in these patients, however, have yielded conflicting results. To
date, the clinical significance of cardiovascular effects after long-term subclinical hypothyr‐
oidism has not been definitively clarified.
The relationship between subclinical hypothyroidism and lipid metabolism is also unclear.
Subclinical hypothyroidism has been associated with variable increases in total cholesterol
and LDL-cholesterol, higher plasma concentrations of oxidized LDL-cholesterol, and incon‐
sistent changes in serum concentrations of HDL-cholesterol. These lipid patterns, however,
may also be affected by age, gender, smoking status, the cause and duration of thyroid dys‐
function, and serum TSH concentration. All of these findings have suggested that there are
no definitive TSH cutoffs for association with lipids.
Subclinical hypothyroidism may also be associated with mood disorders such as major de‐
pression. Moreover, the life-time prevalence of major depressive disorder may be greater in
individuals with than without subclinical hypothyroidism. These findings, however, do not
suggest a direct causal link between subclinical hypothyroidism and mood disturbance.
Studies of the relationships between cognitive function and thyroid hormone levels within
the normal reference range have produced somewhat conflicting results. Some studies have
reported that higher TSH is associated with poorer cognitive function, whereas others found
that higher TSH is correlated with better cognitive performance. These studies indicate that
variations in serum TSH concentrations in individuals having normal thyroid hormone con‐
centrations (fT4, T3) may be related to cognitive impairment, especially in older individuals.
Further investigations of the relationships between serum TSH concentrations and mood
disturbance or cognitive function may be required.
In this chapter, we summarize the definition, causes, diagnosis, and treatment of subclinical
hypothyroidism. We also discuss the clinical effects of this illness, including the effects of
long-term subclinical hypothyroidism on the cardiovascular system, lipid metabolism,
mood disorders and cognitive function.
2. Subclinical hypothyroidism
2.1. Definition
The term subclinical indicates the presence of a disease without obvious symptoms, suggest‐
ing that the disease may be at an early stage. Subclinical thyroid disease is based on the deli‐
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cate sensitivity of the hypothalamic-pituitary-thyroid (HPT) axis. Subclinical hyperthyroid
and hypothyroid conditions are laboratory-based diagnoses. By definition, subclinical hypo‐
thyroidism is characterized by abnormal serum TSH and normal fT4 and T3 concentrations.
In 2002, a scientific review and consensus committee, which included representatives from
the American Thyroid Association (ATA), the American Association of Clinical Endocrinol‐
ogists (AACE), and the US Endocrine Society, convened a panel of experts to define subclin‐
ical thyroid disease, review the literature concerning the risks and benefits of treatment, and
make recommendations about evaluation and population-based screening (Surks et al,
2004). This committee defined subclinical hypothyroidism as “a serum TSH concentration
above the statistically defined upper limit of the reference range when serum free T4 con‐
centration is within its reference range”. However, the definition and the clinical signifi‐
cance of subclinical hypothyroidism are confounded by controversies over the correct upper
limit of the reference range for serum TSH. Meticulous studies from the United States and
elsewhere have addressed this reference range, taking into account the influence of the in‐
clusion or exclusion of subjects with a personal or family history of thyroid disease and pa‐
tients positive for antithyroid antibodies. Because subclinical hypothyroidism is only
detected as an abnormal TSH concentration, defining the TSH reference range is critical. Cir‐
culating TSH is heterogeneous in glycosylation and biological activity. Assays vary widely
because current TSH immunometric assays involve the use of monoclonal antibodies that
differ in specificity and may therefore bind to different TSH isoforms. Therefore, variations
in the reference intervals obtained with different methods reflect differences in epitope rec‐
ognition of different TSH isoforms. Since these differences make it difficult to establish a
universal upper TSH reference limit, the use of thyroid antibody tests has resulted in a pro‐
gressive decrease in the upper limit of the normal range over the last decades, from 10.0-7.0
mU/L to 4.0-5.0 mU/L (Biondi & Cooper, 2008).
Lymphocytic infiltration of the thyroid gland is present in up to 40% of healthy women.
Moreover, competitive immunoassays have shown that 10% of the general population is
positive for antithyroglobulin antibody (Tg Ab) and 12% are positive for detectable antithy‐
roid peroxidase (TPO) antibody levels (Biondi et al, 2005). Furthermore, ultrasound charac‐
teristics can reveal the typical pattern of hypoechogenicity, heterogeneity, and increased
blood flow seen in autoimmune thyroiditis. A hypoechoic or irregular echo ultrasound pat‐
tern may precede positivity for TPO Abs in patients with autoimmune thyroid disease, and
TPO Abs may not be detected in more than 20% of individuals with ultrasound evidence of
thyroid autoimmunity (Vejbjerg et al, 2006). A high thyroid autoantibody titer (usually
against TPO Ab and/or Tg Ab, or more rarely, TSH receptor Ab) is frequently associated
with a persistently elevated serum TSH concentration. Although the thyroid gland is usual‐
ly goitrous, it may also be normal or atrophic, its hypoechogenicity at ultrasound evaluation
could allow clinicians to identify individuals with subclinical hypothyroidism due to auto‐
immune disease (Biondi, 2012).
Therefore, it has been recommended that the reference serum TSH concentration be deter‐
mined using blood sampled in the morning from fasting euthyroid subjects with no family
history of thyroid disease, who are not taking any medication, have no visible or palpable
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goiter or pathological thyroid ultrasonography findings, and are not positive for TPO Ab or
Tg Ab (Kratzsch et al, 2005). Evidence from the National Health and Nutritional Examina‐
tion Survey (NHANES III) of a large ‘reference’ population without evidence of thyroid dis‐
ease indicated that 95% of adults have serum TSH concentrations of 0.45-4.12 mU/L,
indicating that the widely applied upper limit of normal for serum TSH of around 4.5 mU/L
remains appropriate (Hollowell et al, 2001). A panel of experts has classified subjects with
subclinical hypothyroidism into two categories, based on the degree of serum TSH elevation
and pathophysiological consequences; these include patients with mild (4.5-10 mU/L) and
more severely elevated (TSH>10 mU/L) serum TSH (Surks et al, 2004).
Subclinical hypothyroidism should be diagnosed only after a detailed personal and family
history, pharmacological evaluation and an accurate clinical assessment. Some familial dis‐
orders, including a family history of autoimmune thyroid disease and/or endocrine or sys‐
temic autoimmune disorders, and genetic disorders such as Down, Turner and Klinefelter
syndromes, should be investigated to identify subjects with an increased predisposition to
developing autoimmune thyroiditis. In addition, a high thyroid autoantibody titer is fre‐
quently associated with a persistently elevated serum TSH concentration. The ultrasono‐
graphic hypoechogenicity of the thyroid gland can be used to identify individuals with
subclinical hypothyroidism due to autoimmune disease (Wilson & Curry, 2005).
Prior to treatment, patients should be evaluated for transient and false causes of mild in‐
creases in TSH. Reference TSH ranges by age, race and body mass index can help avoid mis‐
classifying patients with increased serum TSH (Biondi, 2012). Interestingly, serum TSH
concentrations are higher in white than in black populations, suggesting that TSH is influ‐
enced by genetics and ethnicity/race. Moreover, increased serum TSH might not always re‐
flect mild thyroid hormone deficiency in elderly subjects from iodine sufficient areas
because the distribution of serum TSH shifts to higher concentrations with age. An in‐
creased serum TSH concentration in older individuals may reflect recovery from acute ill‐
ness or the use of drugs that can interfere with thyroid function (Surks et al, 2004). Since
serum TSH concentrations are higher in overweight and obese individuals than in lean sub‐
jects, subclinical hypothyroidism may be falsely diagnosed in overweight and obese pa‐
tients, especially in those negative for thyroid autoantibodies. However, this altered thyroid
hormone pattern can be reversed by losing weight (Biondi, 2010).
2.2. Causes
The most frequent causes of subclinical hypothyroidism are autoimmune thyroiditis and
previous treatment for hyperthyroidism. In about 60-80% of patients, subclinical hypothyr‐
oidism has been associated with TPO Abs, a marker of chronic lymphocytic (Hashimoto’s)
thyroiditis. Hashimoto’s thyroiditis is more common in females than in males, with the
overall incidence increasing with age in both sexes. Transient or persistent increases in se‐
rum TSH may occur after subacute, post-partum or painless thyroiditis and after an infiltra‐
tive disease (Riedel’s thyroiditis, amyloidosis, hemochromatosis and cystinosis) or infectious
disorder of the thyroid gland. Patients treated for overt thyroid failure often have subclinical
hypothyroidism because of inadequate thyroid hormone supplementation, poor adherence,
Current Topics in Hypothyroidism with Focus on Development168
drug interactions, or inadequate monitoring of treatment (Cooper & Biondi, 2012). Between
17.6% and 30% of patients with overt hypothyroidism were reported to have subclinical thy‐
roid disease due to inadequate thyroid hormone supplementation (Canaris et al, 2000).
Subclinical hypothyroidism may also result from therapies that destroy thyroid tissue, such
as thyroid surgery, radioiodine treatment or external radioiodine therapy. Mild, overt hypo‐
thyroidism frequently occurs after external radiotherapy of the head and neck area and de‐
velops gradually within the first year, with a risk that appears to be dose-dependent (Biondi
& Cooper, 2008). Radioiodine treatment of hyperthyroidism in patients with Graves’ disease
results in hypothyroidism in at least 50% of patients, depending on the dose administered.
Partial thyroidectomy for hyperthyroidism or nodular goiter has been associated with a sim‐
ilar risk for the development of hypothyroidism. Subclinical hypothyroidism soon after ra‐
dioiodine treatment or partial thyroidectomy may be a transient phenomenon, not always
indicative of progressive or permanent hypothyroidism. Even in the absence of ablative thy‐
roid treatment, it has been estimated that 5-20% of patients with Graves’ disease will even‐
tually develop hypothyroidism (Boelaert et al, 2009).
Other causes of subclinical hypothyroidism include autoimmune diseases, such as type I
diabetes mellitus and Addison’s disease. Down and Turner syndromes have also been asso‐
ciated with the development of overt and subclinical hypothyroidism. The risk of subclinical
hypothyroidism during pregnancy is considerable in women identified during the first tri‐
mester as being positive for antithyroid antibodies (Wilson & Curry, 2005). Non-thyroidal
illness may be associated with a transient and modest increase in serum TSH, especially
during the recovery phase, although in most of these patients an increase in TSH concentra‐
tion reflects underlying thyroid disease. Several drugs, including iodine-containing com‐
pounds such as radiographic contrast agents, lithium carbonate, cytokines and interferon,
may induce subclinical or overt hypothyroidism, particularly in patients with underlying
autoimmune thyroiditis (Biondi, 2012).
It is necessary to distinguish subclinical hypothyroidism from other causes of physiological,
artificial, or transiently increased serum TSH. Serum TSH concentrations should be meas‐
ured 3-6 months later to rule out a laboratory error or a transient increase caused, for exam‐
ple, by drugs that interfere with thyroid function, by thyroiditis, and by possible toxic injury
to the thyroid gland (Cooper & Biondi, 2012). Serum TSH concentrations are higher in
healthy elderly than in healthy young people because of a shift in TSH distribution with age.
Rarely, laboratory patterns indistinguishable from subclinical hypothyroidism are observed
in patients with TSH-receptor mutations causing mild TSH resistance, mutations that can af‐
fect up to 0.6% of Caucasian people. Clues to the presence of this disorder are a family histo‐
ry of increased serum TSH concentrations and an absence of thyroid autoimmunity (Jordan
et al, 2003). Serum TSH concentrations are higher in overweight and obese individuals,
which may result in a false diagnosis of subclinical hypothyroidism. Mild increases in serum
TSH concentration in obese people are usually associated with serum T3 concentrations at
the upper limit of the normal range. The latter may be due to increased de-iodinase activity,
which acts as a compensatory mechanism during fat accumulation to increase energy expen‐
diture. This altered thyroid hormone pattern can be reversed by weight loss. Table 1 shows
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the comparison of causes between subclinical hypothyroidism and elevated serum TSH con‐
centrations that are not associated with persistent subclinical hypothyroidism (Biondi &
Cooper, 2008) (Cooper & Biondi, 2012).
Causes of subclinical hypothyroidism
1. Chronic autoimmune thyroiditis
: family history of autoimmune thyroid disease, history of associated autoimmune diseases, Down syndrome,
Turner’s syndrome, etc.
2. Thyroid injury
: partial thyroidectomy, external radiotherapy of head and neck, radioactive iodine therapy, etc.
3. Infiltrative disease of thyroid gland
: Riedel’s thyroiditis, amyloidosis, sarcoidosis, hemochromatosis, cystinosis, AIDS, primary thyroid lymphoma
4. Persistent TSH increase after an episode of subacute thyroiditis, post-partum thyroiditis, painless thyroiditis
5. Drugs
: iodine, iodine-containing medications such as amiodarone, radiographic contrast agents, lithium carbonate,
carbonate, cytokines (interferon alfa), aminoglutetimide, ethionamide, sulfonamides, sulfonylureas
6. Inadequate replacement theray for overt hypothyroidism
7. Toxic substances, industrial and environmental agents
8. TSH receptor gene mutations
Causes of elevated serum TSH concentrations that are not associated with persistent subclinical
hypothyroidism
1. Laboratory analytic problems
: assay variability, abnormal TSH isoform, heterophilic antibodies, etc.
2. Elderly patients with small increases in serum TSH level
3. Obesity
4. Pituitary problem
: pituitary adenoma, isolated pituitary resistance to thyroid hormone, etc.
5. Renal dysfucntion
6. Adrenal insufficiency
7. After withdrawal of thyroid hormone therapy in euthyroid patients
8. Recovery phase of euthyroid sick syndrome
Table 1. Causes of elevated serum TSH concentration
2.3. Prevalence and natural history
The prevalence of subclinical hypothyroidism in adults has been reported to range from
4%  to  20%  (Cooper  &  Biondi,  2012).  This  wide  range  reflects  important  differences  in
race and dietary iodine intake, as well as patient age, gender, body mass index and dif‐
ferences  in  TSH evaluation  methods.  Large,  population-based screening studies,  includ‐
ing the  Whickham Survey (Tunbridge et  al,  1977),  NHANES III  (Hollowell  et  al,  2001),
and the  Colorado thyroid prevalence  study (Canaris  et  al,  2000),  have provided impor‐
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tant epidemiological data about subclinical hypothyroidism. According to the Whickham
Survey,  which  defines  subclinical  hypothyroidism  as  serum  TSH  concentrations  >6
mU/L, this condition was present in 7.5% of females and 2.8% of males. TSH concentra‐
tions  did  not  vary  with  age  in  males  but  increased  markedly  in  females  after  age  45
years.  Serum TSH concentration was not  age-related in women negative for  antithyroid
antibodies.  The NHANES III  study,  which defined subclinical  hypothyroidism as serum
TSH >4.6 mU/L,  reported that  4.3% of individuals had subclinical  hypothyroidism. TPO
Abs were significantly associated with hypothyroidism,  were more prevalent  in  women
than in men, increased with age, and were more prevalent in whites than in blacks. The
Colorado  study,  which  defined  subclinical  hypothyroidism  as  serum  TSH  >5.1  mU/L,
showed that  serum TSH concentrations  were  elevated in  9.5% of  subjects,  and that  the
percentage  increased  with  each  decade  of  age  in  women  but  not  in  men.  All  of  these
surveys reported that  the prevalence of  subclinical  hypothyroidism was higher  in  older
populations.  This  disease  is  more  common  in  iodine-sufficient  than  in  iodine-deficient
countries, suggesting that iodine supplementation may increase its incidence.
The natural history of subclinical hypothyroidism depends on the underlying cause and
the  characteristics  of  each  patient.  However,  long-term  outcome  data  on  patients  with
subclinical hypothyroidism are rare, making it difficult to define the definitive course of
this  disease.  Subclinical  hypothyroidism  may  be  progressive  or  reversible.  With  a  pro‐
gression rate of  only 5% per year,  it  is  reasonable to assume that,  especially in patients
with  serum  TSH  concentrations  ≤10  mU/L,  subclinical  hypothyroidism  may  not  be
caused  by  the  progression  of  any  specific  disease  state  (Wilson  &  Curry,  2005).  One
large follow up study showed that,  of  patients with modestly elevated serum TSH con‐
centrations, 60% show a spontaneous return to the reference range during a mean 5 year
follow-up  period  (Meyerovitch  et  al,  2007).  Moreover,  many  patients  with  non-autoim‐
mune thyroiditis may develop transient TSH elevation.
In a significant number of patients, especially those who are older, female, and positive for
TPO Abs, there is an increased risk of progression to overt hypothyroidism. The Whickham
cohort survey, with a 20-year follow-up period, showed that the annual rate of progression
from subclinical to overt hypothyroidism was 2.6% in patients negative for thyroid antibod‐
ies, but 4.3% if TPO Abs were present. Transient expression of TSH-receptor blocking anti‐
bodies may explain the improvements in thyroid function and the progressive TSH
normalization that may be observed in some patients with autoimmune hypothyroidism.
The annual rate of progression to overt disease was about 4% in women with increased se‐
rum TSH and positive for antithyroid antibodies, 2-4% in women with increased serum TSH
concentrations alone, and 1-3% in women with only antithyroid antibodies. Serum TSH con‐
centrations tend to return to normal more frequently in people with concentrations of 4-6
mU/L, whereas TSH concentrations of 10-15 mU/L are associated with a reduced rate of nor‐
malization of thyroid function. The annual rate of progression to overt hypothyroidism in
patients with subclinical hypothyroidism induced by radioiodine or surgery is 2-6%. Preg‐
nant women with Hashimoto thyroiditis also are at high risk of disease progression. High
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dose iodine intake is also associated with an increased risk of progression to overt hypothyr‐
oidism (Biondi & Cooper, 2008).
The risk of progression from subclinical to overt hypothyroidism is less common, where‐
as the recovery of thyroid function is more common, in children and adolescents than in
adults.  Progression  from mild  to  overt  hypothyroidism may  be  related  to  the  cause  of
thyroid  hormone  deficiency,  the  basal  TSH  concentration,  and  the  age  of  the  patient.
Transient  expression  of  TSH-receptor  blocking  antibodies  may  explain  the  recovery  of
thyroid  function  in  some  patients  (Biondi  &  Cooper,  2008).  Patients  previously  diag‐
nosed with subclinical hypothyroidism should be reevaluated to determine whether this
condition is  persistent.  This  may be accomplished by progressive reduction in LT4 dos‐
age followed by serial TSH testing.
2.4. Consequences of subclinical hypothyroidism
Subclinical hypothyroidism may be associated with adverse cardiovascular events, cardiac
dysfunction, lipid metabolism, and neuropsychiatric symptoms. To date, however, there is
insufficient evidence regarding the association between long-term subclinical hypothyroid‐
ism and systemic sequelae.
2.4.1. The cardiovascular system and the risk of heart failure
Cardiovascular diseases are the most common causes of death worldwide, primarily affect‐
ing older adults. Abnormal TSH concentrations may be a novel cardiac risk factor. Even
mildly altered thyroid status has been reported to affect serum cholesterol concentrations,
heart rhythm and rate, ventricular function, risk of coronary artery disease, and cardiovas‐
cular mortality. Patients with subclinical hypothyroidism may have depressed systolic func‐
tion at rest, and left ventricular diastolic dysfunction at rest and during exercise. Vascular
function may also be impaired by thyroid hormone deficiency. However, the risks of cardio‐
vascular and heart failure in patients with subclinical hypothyroidism remain unclear. Sev‐
eral large scale meta-analyses have assessed the risks of cardiovascular and all-cause
mortality in patients with subclinical hypothyroidism. In one meta-analysis, cardiovascular
mortality was higher in patients <65 years old with subclinical hypothyroidism, but not in
older people (Razvi et al, 2008). A second meta-analysis confirmed that subclinical hypo‐
thyroidism was associated with modestly increased cardiovascular risks of coronary heart
disease and total mortality (Ochs et al, 2008). In addition, reanalysis of the data from the
Whickham Survey cohort showed that systolic and diastolic blood pressures and total cho‐
lesterol concentrations were higher in patients with subclinical hypothyroidism than in con‐
trols in a euthyroid state (Razvi et al, 2010). However, a large prospective cohort study of
559 subjects aged 85 year, including subclinical hypothyroidism was present in 30 patients
and 21 individuals monitored for 4 years, provided opposite evidences. This study found
that raised serum TSH concentrations was associated with decreased mortality in individu‐
als older than 85 years, and this might be attributed to a lower metabolic rate. In this study,
individuals with subclinial hypothyroidism had lower all-causes and cardiovascular mortal‐
ity than clinically euthyroid individuals, although serum cholesterol levels were higher
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(Gussekloo et al, 2004). Similarly, other studies reported that subclinical hypothyroidism
was not associated with increased overall mortality risk in elderly subjects. Crucially, a
meta-analysis of individual participant data from 11 prospective cohort studies has shown
no overall association of subclinical hypothyroidism with coronary heart disease events,
mortality or total mortality (Rodondi et al, 2010). However, significant associations were ob‐
served when the degree of serum TSH elevation was stratified, in that coronary heart dis‐
ease events and mortality risks were significantly increased in individuals with serum TSH
>10 mU/L. This correlation with greater biochemical abnormality was consistent with stud‐
ies in patients with heart failure, in that incident heart failure risk was evident, or of greater
magnitude, when serum TSH was > 10 mU/L. By contrast with studies suggesting that the
risk of coronary heart disease decreased with patient age, findings of this meta-analysis
showed no interaction between mortality due to coronary heart disease and age.
In summary, several prospective, population-based cohort studies found that subclinical hy‐
pothyroidism was associated with increased risks of cardiovascular disease and mortality,
whereas other, similar studies showed no correlation between subclinical hypothyroidism
and the incidence of and mortality due to coronary heart disease.
2.4.2. Lipid profiles
Thyroid hormones have varied effects on lipid metabolism, because thyroid function regu‐
lates cholesterol synthesis and degradation and mediates the activity of key enzymes in
these pathways. Thyroid hormones reduce cholesterol concentration mainly through the in‐
creased expression of low-density lipoprotein (LDL)-cholesterol receptors in the liver and
peripheral organs (Duntas & Brenta, 2012). Overt hypothyroidism increases the serum con‐
centrations of total and LDL-cholesterol, as well as altering the concentrations of other lipo‐
proteins and apolipoproteins. In contrast, lipid changes in individuals with subclinical
hypothyroidism are considerably less marked, with studies showing inconsistent results.
For example, studies comparing lipid profiles in subclinical hypothyroid patients and euthy‐
roid controls have found that subclinical hypothyroidism was associated with lipid abnor‐
malities, especially increases in total and LDL cholesterol, but its effects on the
concentrations of high-density lipoprotein (HDL)-cholesterol, triglycerides and lipopro‐
tein(a) were unclear (Cappola & Ladenson, 2003) (Duntas & Wartofsky, 2007).
The United States Colorado study, with a population sample of 25,862 subjects, showed that
patients with subclinical hypothyroidism had higher total cholesterol concentrations than
euthyroid individuals (Canaris et al, 2000). In the NHANES III cohort, cholesterol and trigly‐
ceride concentrations were higher in patients with subclinical hypothyroidism than in eu‐
thyroid subjects, but these effects were no longer observed after adjusting for variables such
as sex, race, age, and treatment with lipid lowering drugs (Hollowell et al, 2001). In contrast,
recent studies that distributed patients into groups based on the severity of dyslipidemia
found that the incidence of subclinical hypothyroidism was highest in the group with the
highest serum cholesterol concentrations (Bindels et al, 1999). Lipid patterns were particu‐
larly altered in patients with subclinical hypothyroidism and a serum TSH concentration >10
mU/L, especially in older patients. The discrepancy between these study results may be due
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to the heterogeneity of the populations studied, including differences in TSH concentrations
used to define subclinical hypothyroidism and selection criteria based on age, sex, race,
smoking history, and insulin resistance. Although hyperinsulinemia may increase the hepat‐
ic output of very low-density lipoprotein (VLDL) particles, hypothyroidism may suppress
their removal, resulting in a net accumulation of modified lipoproteins. Moreover, LDL par‐
ticles in subjects with subclinical hypothyroidism have an impaired composition, becoming
triglyceride-rich lipoproteins (Duntas & Brenta, 2012). VLDL remnants and intermediate-
density lipoproteins (IDL) tend to accumulate in the circulation. However, the fractional
clearance rates of triglycerides and cholesteryl esters have been reported equal in patients
with subclinical hypothyroidism and controls, indicating that lipolysis and the removal of
remnant triglyceride rich lipoproteins were normal. Nevertheless, transfer of triglycerides to
HDL was lower in subjects with subclinical hypothyroidism than in controls.
In summary, the association between lipid patterns and subclinical hypothyroidism remains
unclear. This may reflect differences in population-based studies, as well as differences in
age, gender, and ethnicity of the subjects examined. Taken together, these findings have re‐
sulted in the formulation of a hypothesis, that there is no TSH cutoff threshold associated
with lipids. However, smoking and insulin resistance may play important roles in media‐
ting the effects of subclinical hypothyroidism on serum lipids.
2.4.3. Mood and cognitive changes
The relationships between overt thyroid disease and mood impairment and cognitive dys‐
function have been described. Overt hypothyroidism is a frequent cause of major depressive
disorder, including melancholia, and may lead to reversible dementia. Several relatively
small-volume studies found more hypothyroid associated signs and symptoms of mood dis‐
orders in individuals with subclinical hyperthyroidism than in euthyroid individuals. Sub‐
clinical hypothyroidism may be associated with current depressive symptoms, current
major depression and a lifetime history of major depression (Joffe et al, 2012) (Chueire et al,
2007). These studies have reported a higher frequency and/or severity of current depressive
symptoms in young or middle-aged adults with subclinical hypothyroidism than in match‐
ed euthyroid controls. Moreover, the lifetime prevalence of major depressive disorder has
been reported higher in individuals with subclinical hypothyroidism than in euthyroid sub‐
jects. These findings suggest an association, but not necessarily a direct causal relationship,
between subclinical hypothyroidism and mood disturbance or disorders. Recent studies,
however, have suggested that patients with primary major depressive illness have a re‐
duced rate of response to antidepressants and are at greater risk of chronicity of depression
if they have comorbid subclinical hypothyroidism.
Although many studies have assessed the relationship between mild hypothyroidism and
cognitive dysfunction, these studies have produced somewhat conflicting findings. A recent
cross-sectional study of 5865 patients in England aged ≥65 years with no known thyroid dis‐
ease (168 with subclinical hypothyroidism defined by TSH >5.5 mIU/L) was performed in
primary care practices to evaluate the association with mood and cognitive changes. This
study found no associations between mild hypothyroidism and cognitive function, depres‐
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sion, and anxiety (Roberts et al, 2006). In contrast, evaluation of brain function by functional
magnetic resonance imaging (MRI) in patients with overt and subclinical hypothyroidism
and euthyroid subjects suggested that working memory, but not other memory functions,
was impaired by subclinical hypothyroidism, with impairment more severe in patients with
overt hypothyroidism (Zhu et al, 2006). Whereas some studies included only older subjects,
other studies include broad ranges of age groups, limiting the conclusions that can be drawn
from these data. Perhaps, the most problematic methodological issue in these studies is their
reliance on limited measures of cognitive function, especially the Mini Mental State Exami‐
nation, which provides a very limited assessment of cognition and is likely relatively insen‐
sitive to potentially subtle, although clinically meaningful, neuropsychological impairments.
This may explain the discrepancy among studies, with some finding and others not finding
an association between cognitive alterations and subclinical hypothyroidism (Joffe et al,
2012). Nonetheless, these studies have shown that younger adults with subclinical hypo‐
thyroidism may experience mild cognitive abnormalities, generally difficulties with selec‐
tive attention and new learning. Studies in older adults have found that subclinical
hypothyroidism may be associated with deficits in attention, in some aspects of executive
functioning, verbal and visual recall, and in reaction time, but these deficits may differ in
older and younger individuals, and in men women (Samuels et al, 2008).
The relationship between subclinical hypothyroidism and vulnerability to dementia, espe‐
cially Alzheimer’s disease, has been evaluated in older adults. Although high TSH concen‐
trations were associated with an increased risk of developing Alzheimer’s disease or
dementia, the association between subclinical hypothyroidism and dementia is unclear.
Moreover, the brains of older adults may show differential sensitivity, manifesting as cogni‐
tive changes, to small perturbations of the thyroid axis.
In summary, the pattern and severity of mood and cognitive symptoms in patients with sub‐
clinical hypothyroidism have not been fully delineated, although both depressive symptoms
and depressive syndromes may occur with increased frequency. It is difficult to distinguish
euthyroid subjects from patients with subclinical hypothyroidism based on these symptoms.
Subclinical hypothyroidism may also be associated with current cognitive impairment and
the further risk of cognitive decline. In addition, these symptoms are probably related to dis‐
ease severity, disease duration, and individual sensitivity to thyroid hormone deficiency.
Age may also affect the correlations between subclinical hypothyroidism and mood, cogni‐
tion, and Alzheimer’s disease. Larger randomized controlled studies are necessary to assess
the importance of mood and cognitive function in both younger and older age groups, espe‐
cially in individuals with minimally elevated TSH.
2.5. Treatment
There has been much discussion about the screening and treatment of patients with subclini‐
cal hypothyroidism. Because of the difficulties in interpreting data from many different
sources, the AACE, the US Endocrine Society and the ATA convened a panel in 2002 to for‐
mulate evidence-based guidelines for the diagnosis, screening, and treatment of subclinical
hypothyroidism (Surks et al, 2004). The consensus panel recommended that patients with
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elevated serum TSH undergo repeat testing, along with a serum fT4 measurement, from 2
weeks to 3 months later. If these tests confirm subclinical hypothyroidism, further evalua‐
tion is required, including clinical assessment of signs and symptoms; history taking to de‐
termine if the patient had been previously treated for hyperthyroidism (e.g., with
radioiodine therapy or partial thyroidectomy), or if there is a family history of thyroid dis‐
ease; and determination of the occurrence of thyroid enlargement. These patients should al‐
so be screened for hyperlipidemia. Although the presence of TPO Ab increases the risk of
progression to overt hypothyroidism, the panel found insufficient evidence to recommend
for or against obtaining titers because determining the presence of antibodies does not
change patient management.
The panel found good evidence that subclinical hypothyroidism is associated with progres‐
sion to overt hypothyroidism, and fair evidence that serum TSH concentrations >10 mU/L
are associated with elevated total and LDL cholesterol concentrations. The panel recom‐
mended that patients with serum TSH concentrations >10 mU/L be treated with levothyrox‐
ine sodium (LT4). There is no conclusive evidence that treatment will improve symptoms or
associated clinical conditions such as hyperlipidemia; however, because 2-10% of patients
progress to overt hypothyroidism, treatment may prevent symptom development in pa‐
tients with low fT4 concentrations. Most other guidelines and expert views also recommend
treatment of subclinical hypothyroid patients with TSH concentrations >10 mU/L (Biondi &
Cooper, 2008) (Gharib et al, 2005) (Khandelwal & Tandon, 2012) (Vaidya & Pearce, 2008).
Treatment of asymptomatic patients with serum TSH concentrations between 4.5 and 10
mU/L remains unclear. The panel recommended that only pregnant women and women
contemplating pregnancy be treated for subclinical hypothyroidism and TSH concentrations
≤10 mU/L, based on a possible association between high TSH and subsequent neuropsycho‐
logical complications in offspring. According to recent ATA guidelines, if a woman is hypo‐
thyroid prior to pregnancy, it recommended that her dosage be adjusted so that TSH is
below 2.5 mU/L prior to conception (Stagnaro-Green et al, 2011). This lowers the risk of the
TSH elevating in the first trimester. If a woman is diagnosed as hypothyroid during preg‐
nancy, she should be treated without delay, with the goal of restoring her thyroid levels to
normal as quickly as possible. In pregnancy, overt hypothyroidism is defined as a TSH
above 2.5 mU/L, along with a decreased fT4 level. Even if a woman has normal fT4, if TSH is
above 10.0 mU/L during pregnancy, it is also considered to be overt hypothyroidism. Sub‐
clinical hypothyroidism is defined as TSH between 2.5 and 10 mU/L, with a normal fT4 lev‐
el. During the first trimester, the TSH level should be maintained at a level of between 0.1
and 2.5 mIU/L, 0.2 to 3.0 mIU/L during the second trimester, and 0.3 to 3.0 mIU/L in the
third trimester. By the time a woman is four to six weeks pregnant, her dose of thyroid med‐
ication will usually need to be increased, potentially by as much as 50 percent. A woman
with thyroid autoimmunity with positive thyroid antibodies who has normal TSH levels in
the early stages of her pregnancy is still at increased risk of becoming hypothyroid at any
point in the pregnancy. She should be monitored regularly through the pregnancy for ele‐
vated TSH (Stagnaro-Green et al, 2011).
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The panel recommended against routine treatment of patients with subclinical hypothyroid‐
ism and serum TSH ≤10 mU/L, as available data do not support a clear-cut benefit for early
treatment of these patients. However, in a separate consensus statement, these societies rec‐
ommended that most subclinical hypothyroid patients be considered for treatment, with the
key determinant being the clinical judgment of the provider (Gharib et al, 2005). Recently
some experts further consolidated the available evidence and recommended LT4 therapy in
women who are pregnant, planning pregnancy, have ovulatory dysfunction, or are infertile;
as well as in patients with symptoms, goiter, anti-TPO antibodies, and high background car‐
diovascular risk, including those with hypertension, hypercholesterolemia, insulin resist‐
ance or diabetes, isolated diastolic dysfunction, or evidence of impaired endothelial function
(Biondi & Cooper, 2008) (Khandelwal & Tandon, 2012). Current evidence suggests that mid‐
dle-aged individuals are more likely to benefit from treatment than elderly individuals.
Asymptomatic individuals should undergo repeat thyroid function tests every 6 to 12
months. There is also insufficient evidence to support therapeutic intervention in patients
with symptoms of hypothyroidism and serum TSH concentrations between 4.5 and 10
mU/L. The panel suggested, however, that these patients be started on LT4, with treatment
continued only in those experiencing symptomatic benefit (Woeber, 2005).
Thyroid hormone preparations available for treatment of hypothyroidism include levothyr‐
oxine sodium (L-thyroxine; LT4) and liothyronine sodium (L-triiodothyronine; LT3). LT4 is
synthetically produced but identical to T4 secreted by the thyroid. LT4 is the preferred drug
because its administration closely mimics glandular secretion and its conversion to T3 is ap‐
propriately regulated by tissues, which maintain a steady and adequate supply. Its long
half-life of 7 days allows single daily dose administration and results in only small fluctua‐
tions in serum concentrations between daily doses (Khandelwal & Tandon, 2012) (Woeber,
2005). Serum T4 concentrations peak 2-4 hours after an oral dose and remain above normal
for approximately 6 hours in patients receiving daily replacement therapy. LT4 is also recog‐
nized to have a narrow toxic to therapeutic ratio, with excess amounts having significant
clinical consequences. Adverse effects of over-replacement include the risk of bone loss, es‐
pecially in postmenopausal women, and increased risk of atrial fibrillation. Transient scalp
hair loss can also take place during the first few weeks of LT4 treatment. Allergic reactions
have been rarely reported, but these were almost always reactions to dye or other inactive
constituents. LT3 is a synthetic form of natural T3 hormone with the same actions as the nat‐
ural product. It has a half-life of 1 day, thus requiring multiple doses daily. Another disad‐
vantage of LT3 is the increase in serum T3 concentration to supranormal values, up to
250-600%, in the absorption phase, during which many patients report adverse effects, espe‐
cially palpitations (Wiersinga, 2001) (Woeber, 2005). Treatment with LT3 should therefore be
considered only in patients with LT4 maldigestion or malabsorption, as well as in patients
who cannot convert T4 to T3 (Celi et al, 2011). Otherwise, it is not intended as sole mainte‐
nance therapy in patients with hypothyroidism. Combined treatment with LT4 and LT3 has
been attempted to more closely mimic the thyroid secretion patterns of T4 and T3. However,
there is no currently available preparation containing both LT4 and LT3 in combination that
adequately reproduces the relative quantities of these hormones produced by the human
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thyroid gland. Furthermore, no preparation results in a pattern of sustained release of thy‐
roid hormones similar to that of the human thyroid (Woeber, 2005).
The goal of treatment is to restore the individual to a euthyroid state, with resolution of
signs and symptoms of hypothyroidism. Chronic under- or over- replacement is common in
clinical practice, with over-treatment occurring in about 20% of LT4-treated patients (Cana‐
ris et al, 2000) (Parle et al, 1993). The rapidity with which the euthyroid state should be at‐
tained is dictated by several factors, notably the age of the patient, the duration and severity
of hypothyroidism and the presence of other co-morbid conditions, specifically cardiac dis‐
ease. It has been recommended that LT4 be taken as a single daily dose on an empty stom‐
ach at least 30 minutes before breakfast. Individual LT4 requirements are greatly dependent
on an individual’s lean body mass, rather than on total body weight. Patients with subclini‐
cal hypothyroidism and minimal thyroid hormone deficiency may be controlled with daily
LT4 dosages as low as 25-50 μg. After initiation of thyroid hormone therapy, the symptoms
and signs of hypothyroidism should be assessed at each follow-up visit. The earliest clinical
response to LT4 replacement is usually diuresis and weight loss, leading to mobilization of
interstitial fluid as glycosaminoglycans are degraded. Weight loss is predominantly due to
fluid loss, and is unlikely to exceed 5 kg, even in obese patients, especially if pre-treatment
TSH concentrations were only modestly elevated. Two months after initiating therapy, the
minimum time required for the pituitary-thyroid axis to re-set, the dose should be moni‐
tored by measuring serum TSH, with or without serum T4. Serum TSH should be main‐
tained in the lower half of the normal range (0.5-2.0 mU/L) (McDermott, 2009).
An important cause of persistently elevated TSH despite an adequate replacement dose of
LT4 is patient non-compliance. These patients may have elevated TSH with high normal or
elevated fT4, as they may not take LT4 for days and then take several pills a few days before
testing. These patients do not require changes in LT4 dose; rather, emphasis should be
placed on compliance with therapy and thyroid function tests should be repeated in 3-4
weeks. Other causes of persistently elevated TSH despite an apparently adequate dose of
LT4 include malabsorption and interference by drugs. Coeliac disease should be excluded,
as it may be present in patients with hypothyroidism because of its autoimmune nature. The
presence of heterophilic antibodies in a patient’s serum can also result in an artificial eleva‐
tion of TSH (Khandelwal & Tandon, 2012).
3. Conclusion
Subclinical hypothyroidism is a frequent clinical problem, readily diagnosed by laboratory
methods. Since most patients with this condition are asymptomatic, screening is required to
detect the condition in most cases. As there is insufficient evidence to support population-
based data, the associations between subclinical hypothyroidism and adverse clinical out‐
comes remain unclear. Subclinical hypothyroidism was recently reported to be associated
with increased risks of cardiovascular disease and heart failure. Subclinical hypothyroidism
may or may not be correlated with other systemic conditions, such as changes in lipid me‐
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tabolism, mood and cognition, with the clinical significance of these systemic effects after
long-term subclinical hypothyroidism being unclear. Findings suggest that these systemic
sequelae of subclinical hypothyroidism are associated with increased disease severity, dis‐
ease duration, age, and individual sensitivity to thyroid hormone deficiency.
The benefits of treatment of subclinical hypothyroidism remain unclear, despite the poten‐
tial risk of progression to overt disease, and there is no definite consensus on thyroid hor‐
mone and TSH cutoff values at which treatment should be contemplated. It has been
recommended that all patients with subclinical hypothyroidism with TSH >10 mU/L or
showing symptoms be treated, as should all pregnant women with any degree of subclinical
hypothyroidism. The benefits of treatment of asymptomatic patients with subclinical hypo‐
thyroidism and serum TSH ≤ 10 mU/L remain unclear. Most expert groups have recom‐
mended LT4 therapy for patients with a mild degree of subclinical hypothyroidism (TSH ≤
10 mU/L) only if they have symptoms, goiter, anti-TPO antibodies or infertility. Adequacy
of treatment is monitored by measuring serum TSH and fT4 concentrations. Special consid‐
erations are needed in pregnant women, children, elderly patients and patients with cardiac
disease. Under- and over- treatment are common in clinical practice and should be avoided.
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